SUNPHARMA · NSE
Sun Pharmaceutical
Phase 4 · Capital Return
Profitable, cash-generative, and returning capital to shareholders through dividends.
Phase 1
Startup
Phase 2
Hyper Growth
Phase 3
Operating Leverage
Phase 4
Capital Return
Phase 5
Decline
Revenue growth (YoY)
11.2%
Mar 2026 vs Mar 2025
Net profit growth (YoY)
5.0%
Operating cash flow
₹12419 Cr
Mar 2026
Returning capital?
Yes
Last dividend ex-date 2026-07-06
Revenue, profit & operating cash flow
₹ crore, by fiscal year
RevenueNet profitOperating cash flowRevenue ends at ₹58462 Cr. Net profit ends at ₹11509 Cr. Operating cash flow ends at ₹12419 Cr.
Judge management on
Capital allocation — are dividends sized sensibly against free cash flow?
Key metric to watch
Free cash flow and the dividend payout ratio.
Typically valued on
Price/earnings and dividend yield.
| Fiscal year | Revenue | Net profit | Operating cash flow |
|---|---|---|---|
| Mar 2021 | ₹33498 Cr | ₹2272 Cr | ₹6170 Cr |
| Mar 2022 | ₹38654 Cr | ₹3389 Cr | ₹8985 Cr |
| Mar 2023 | ₹43886 Cr | ₹8513 Cr | ₹4959 Cr |
| Mar 2024 | ₹48497 Cr | ₹9610 Cr | ₹12135 Cr |
| Mar 2025 | ₹52578 Cr | ₹10965 Cr | ₹14072 Cr |
| Mar 2026 | ₹58462 Cr | ₹11509 Cr | ₹12419 Cr |
Advertisement